Rockville, MD
USA
- PD/QC/Fill
- Adherent including
- Fixed bed Bioreactors
- Suspension 2 x 200L
- Pre clinical to Phase II
Lyon,
FRANCE
- PD/QC
- Adherent
- Suspension 3 x 200L
- Pre clinical to Phase II
Strasbourg,
FRANCE
- PD/QC/Fill
- Adherent
- Suspension 200/500L
- Pre clinical to Phase III
- Commercial readiness program completed in 2022
Beyond Strasbourg site, ABL will offer additional large scale commercial capacities for manufacturing of viral vectors in 2024